Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity

Journal of Neuroimmunology

Volumn 225, Issue 1-2, 2010, Pages 43-51

  Xing, Bin ^a   Xin, Tao ^b   Zhao, Lingling ^c   Hunter, Randy L ^a   Chen, Yan ^a   Bing, Guoying ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Dopaminergic neurons; GDNF; Microglia; Nitric oxide; Parkinson's disease; PI3K

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MICROGLIA; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTORS; LIPOPOLYSACCHARIDES; MESENCEPHALON; MICROGLIA; NEURONS; NITRIC OXIDE; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE;

EID: 77955662358     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.04.010     Document Type: Article

References (109)

1. Aoi M., Date I., Tomita S., Ohmoto T. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system. Neurol. Res. 2000, 22:832-836.
2. Arimoto T., Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 2003, 12:35-45.
3. Barthwal M.K., Srivastava N., Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep. 2001, 6:297-302.
4. Beal M.F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 1998, 44:S110-S114.
5. Becq H., Bosler O., Geffard M., Enjalbert A., Herman J.P. Anatomical and functional reconstruction of the nigrostriatal system in vitro: selective innervation of the striatum by dopaminergic neurons. J. Neurosci. Res. 1999, 58:553-566.
6. Brunet A., Datta S.R., Greenberg M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 2001, 11:297-305.
7. Carrasco E., Casper D., Werner P. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J. Neurosci. Res. 2007, 85:3109-3117.
8. Cheng F.C., Ni D.R., Wu M.C., Kuo J.S., Chia L.G. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice. Neurosci. Lett. 1998, 252:87-90.
9. Choi D.Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., Shin E.J., Kim H.C., Gash D.M., Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE 2009, 4:e5482.
10. Chung K.K., Thomas B., Li X., Pletnikova O., Troncoso J.C., Marsh L., Dawson V.L., Dawson T.M. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004, 304:1328-1331.
11. Creedon D.J., Tansey M.G., Baloh R.H., Osborne P.A., Lampe P.A., Fahrner T.J., Heuckeroth R.O., Milbrandt J., Johnson E.M. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc. Natl Acad. Sci. USA 1997, 94:7018-7023.
12. Cunningham C., Wilcockson D.C., Campion S., Lunnon K., Perry V.H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 2005, 25:9275-9284.
13. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
14. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
15. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 2000, 74:2213-2216.
16. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 1994, 9:92-97.
17. Ding Y.M., Jaumotte J.D., Signore A.P., Zigmond M.J. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J. Neurochem. 2004, 89:776-787.
18. Du Y., Li X., Yang D., Zhang X., Chen S., Huang K., Le W. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo. Exp. Biol. Med. (Maywood) 2008, 233:881-890.
19. Elkon H., Melamed E., Offen D. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J. Mol. Neurosci. 2004, 24:387-400.
20. Eslamboli A., Cummings R.M., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Kirik D., Annett L.E. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 2003, 184:536-548.
21. Floden A.M., Combs C.K. Microglia repetitively isolated from in vitro mixed glial cultures retain their initial phenotype. J. Neurosci. Meth. 2007, 164:218-224.
22. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., Hartley M., Trevino I., O'Brien D.E., Casey B., Goldberg M.S., Tansey M.G. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 2008, 28:10825-10834.
23. Franke H., Schelhorn N., Illes P. Dopaminergic neurons develop axonal projections to their target areas in organotypic co-cultures of the ventral mesencephalon and the striatum/prefrontal cortex. Neurochem. Int. 2003, 42:431-439.
24. Frebel K., Wiese S. Signalling molecules essential for neuronal survival and differentiation. Biochem. Soc. Trans. 2006, 34:1287-1290.
25. Gao H.M., Hong J.S., Zhang W., Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 2002, 22:782-790.
26. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 2002, 81:1285-1297.
27. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
28. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 2002, 133:27-35.
29. Ghribi O., Herman M.M., Pramoonjago P., Spaulding N.K., Savory J. GDNF regulates the A beta-induced endoplasmic reticulum stress response in rabbit hippocampus by inhibiting the activation of gadd 153 and the JNK and ERK kinases. Neurobiol. Dis. 2004, 16:417-427.
30. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
31. Glazner G.W., Mu X., Springer J.E. Localization of glial cell line-derived neurotrophic factor receptor alpha and c-ret mRNA in rat central nervous system. J. Comp. Neurol. 1998, 391:42-49.
32. Gramsbergen J.B., Sandberg M., Moller Dall A., Kornblit B., Zimmer J. Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin. Brain Res. 2002, 935:47-58.
33. Granziera C., Thevenet J., Price M., Wiegler K., Magistretti P.J., Badaut J., Hirt L. Thrombin-induced ischemic tolerance is prevented by inhibiting c-jun N-terminal kinase. Brain Res. 2007, 1148:217-225.
34. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 2005, 93:105-117.
35. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elsberry D.D., Klein M.C., Gerhardt G.A., Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002, 125:2191-2201.
36. Hashimoto M., Nitta A., Fukumitsu H., Nomoto H., Shen L., Furukawa S. Inflammation-induced GDNF improves locomotor function after spinal cord injury. NeuroReport 2005, 16:99-102.
37. Herrera A.J., Tomas-Camardiel M., Venero J.L., Cano J., Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural. Transm. 2005, 112:111-119.
38. Hirsch E.C., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann. Neurol. 1998, 44:S115-S120.
39. Honda S., Nakajima K., Nakamura Y., Imai Y., Kohsaka S. Rat primary cultured microglia express glial cell line-derived neurotrophic factor receptors. Neurosci. Lett. 1999, 275:203-206.
40. Hong J.S. Role of inflammation in the pathogenesis of Parkinson's disease: models, mechanisms, and therapeutic interventions. Ann. N. Y. Acad. Sci. 2005, 1053:151-152.
41. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 1999, 162:3749-3752.
42. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996, 72:355-363.
43. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2004, 101:665-670.
44. Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.C., Cass W.A., Sullivan P.G., Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 2007, 100:1375-1386.
45. Hunter R.L., Cheng B., Choi D.Y., Liu M., Liu S., Cass W.A., Bing G. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J. Neurosci. Res. 2009, 87:1913-1921.
46. Iravani M.M., Kashefi K., Mander P., Rose S., Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002, 110:49-58.
47. Jana M., Jana A., Liu X., Ghosh S., Pahan K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J. Immunol. 2007, 179:4142-4152.
48. Jenner, P., 2003. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3, S26-36; discussion S36-28.
49. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998, 44:S72-S84.
50. Kawahara K., Yoshida A., Koga K., Yokoo S., Kuniyasu A., Gotoh T., Sawada M., Nakayama H. Marked induction of inducible nitric oxide synthase and tumor necrosis factor-alpha in rat CD40+ microglia by comparison to CD40- microglia. J. Neuroimmunol. 2009, 208:70-79.
51. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 2000, 20:6309-6316.
52. King T.D., Bijur G.N., Jope R.S. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 2001, 919:106-114.
53. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 2000, 16:724-739.
54. Kordower J.H., Palfi S., Chen E.Y., Ma S.Y., Sendera T., Cochran E.J., Cochran E.J., Mufson E.J., Penn R., Goetz C.G., Comella C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 1999, 46:419-424.
55. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
56. Kotake Y., Taguchi R., Okuda K., Sekiya Y., Tasaki Y., Hirobe M., Ohta S. Neuroprotective effect of 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res. 2005, 1033:143-150.
57. Kress G.J., Reynolds I.J. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures. Neurobiol. Dis. 2005, 20:639-645.
58. Lapchak P.A., Miller P.J., Collins F., Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997, 78:61-72.
59. Lawson L.J., Perry V.H., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
60. Le W., Rowe D., Xie W., Ortiz I., He Y., Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001, 21:8447-8455.
61. Lehnardt S., Lachance C., Patrizi S., Lefebvre S., Follett P.L., Jensen F.E., Rosenberg P.A., Volpe J.J., Vartanian T. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 2002, 22:2478-2486.
62. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl Acad. Sci. USA 2003, 100:8514-8519.
63. Li F.Q., Lu X.Z., Liang X.B., Zhou H.F., Xue B., Liu X.Y., Niu D.B., Han J.S., Wang X.M. Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J. Neuroimmunol. 2004, 148:24-31.
64. Li F.Q., Wang T., Pei Z., Liu B., Hong J.S. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. J. Neural. Transm. 2005, 112:331-347.
65. Li G., Cui G., Tzeng N.S., Wei S.J., Wang T., Block M.L., Hong J.S. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J. 2005, 19:489-496.
66. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
67. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
68. Lindvall O., Wahlberg L.U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp. Neurol. 2008, 209:82-88.
69. Liu B., Wang K., Gao H.M., Mandavilli B., Wang J.Y., Hong J.S. Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J. Neurochem. 2001, 77:182-189.
70. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., Hong J.S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 2003, 305:212-218.
71. Malagelada C., Jin Z.H., Greene L.A. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J. Neurosci. 2008, 28:14363-14371.
72. Maswood N., Grondin R., Zhang Z., Stanford J.A., Surgener S.P., Gash D.M., Gerhardt G.A. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol. Aging 2002, 23:881-889.
73. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 1988, 24:574-576.
74. McGeer P.L., Yasojima K., McGeer E.G. Inflammation in Parkinson's disease. Adv. Neurol. 2001, 86:83-89.
75. Nagatsu T., Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell. Mol. Neurobiol. 2006, 26:781-802.
76. Nakanishi H., Tamura A., Kawai K., Yamamoto K. Electrophysiological studies of rat substantia nigra neurons in an in vitro slice preparation after middle cerebral artery occlusion. Neuroscience 1997, 77:1021-1028.
77. Nguyen V.T., Walker W.S., Benveniste E.N. Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-beta. Eur. J. Immunol. 1998, 28:2537-2548.
78. 2-induced neuronal death. Neurobiol. Dis. 2005, 20:141-154.
79. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57:168-175.
80. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 2005, 57:298-302.
81. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
82. Qin H., Wilson C.A., Lee S.J., Zhao X., Benveniste E.N. LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood 2005, 106:3114-3122.
83. Reilly C.E. Glial cell line-derived neurotrophic factor (GDNF) prevents neurodegeneration in models of Parkinson's disease. J. Neurol. 2001, 248:76-78.
84. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998, 82:129-137.
85. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. NeuroSci. 1999, 11:1554-1566.
86. Saavedra A., Baltazar G., Santos P., Carvalho C.M., Duarte E.P. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol. Dis. 2006, 23:533-542.
87. Sarabi A., Hoffer B.J., Olson L., Morales M. GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J. Comp. Neurol. 2001, 441:106-117.
88. Sawada H., Ibi M., Kihara T., Urushitani M., Nakanishi M., Akaike A., Shimohama S. Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons. J. Neurochem. 2000, 74:1175-1184.
89. Schulz J.B., Matthews R.T., Muqit M.M., Browne S.E., Beal M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 1995, 64:936-939.
90. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
91. Shibata H., Katsuki H., Nishiwaki M., Kume T., Kaneko S., Akaike A. Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin. J. Neurochem. 2003, 86:1201-1212.
92. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39:167-174.
93. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 2003, 100:5473-5478.
94. Testa C.M., Sherer T.B., Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 2005, 134:109-118.
95. Timmons S., Coakley M.F., Moloney A.M., C O.N. Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett. 2009, 467:30-35.
96. Ugarte S.D., Lin E., Klann E., Zigmond M.J., Perez R.G. Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J. Neurosci. Res. 2003, 73:105-112.
97. van Weering D.H., Bos J.L. Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation. J. Biol. Chem. 1997, 272:249-254.
98. Vijitruth R., Liu M., Choi D.Y., Nguyen X.V., Hunter R.L., Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2006, 3:6.
99. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., Jeng K.C. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. NeuroSci. 2002, 16:2103-2112.
100. Wang T., Liu B., Qin L., Wilson B., Hong J.S. Protective effect of the SOD/catalase mimetic MnTMPyP on inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuronal-glial cultures. J. Neuroimmunol. 2004, 147:68-72.
101. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 1993, 14:275-285.
102. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
103. Xing B., Liu M., Bing G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J. Neuroimmunol. 2007, 192:89-98.
104. Xing B., Xin T., Hunter R.L., Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J. Neuroinflammation 2008, 5:4.
105. Yasuhara T., Shingo T., Muraoka K., Kobayashi K., Takeuchi A., Yano A., Wenji Y., Kameda M., Matsui T., Miyoshi Y., Date I. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J. Neurosurg. 2005, 102:80-89.
106. Zecca L., Wilms H., Geick S., Claasen J.H., Brandenburg L.O., Holzknecht C., Panizza M.L., Zucca F.A., Deuschl G., Sievers J., Lucius R. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 2008, 116:47-55.
107. Zhang W., Phillips K., Wielgus A.R., Liu J., Albertini A., Zucca F.A., Faust R., Qian S.Y., Miller D.S., Chignell C.F., Wilson B., Jackson-Lewis V., Przedborski S., Joset D., Loike J., Hong J.S., Sulzer D., Zecca L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 2009, [Epub ahead of print].
108. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhou Y., Hong J.S., Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542.
109. Zhou H.F., Liu X.Y., Niu D.B., Li F.Q., He Q.H., Wang X.M. Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol. Dis. 2005, 18:441-449.